Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $0.00 | $21.8K |
| Gross profit | — | — | $17.6K |
| Gross margin | — | — | 80.6% |
| Operating income | -$3.87M | -$3.09M | -$8.91M |
| Operating margin | — | — | -40873.2% |
| Net income | -$4.78M | -$2.44M | -$8.64M |
| Net margin | — | — | -39662.8% |
| EPS (diluted) | -$0.18 | -$0.08 | -$0.25 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$481K | -$3.91M | -$5.41M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total assets | $149K | $6.20M | $5.56M |
| Total liabilities | $5.95M | $2.03M | $7.40M |
| Shareholders' equity | -$5.80M | $4.17M | -$1.83M |
| Retained earnings | -$23.6M | -$26.0M | -$34.7M |
| Shares (wtd avg diluted) | 26.4M | 28.8M | 34.6M |
Every figure is extracted from JUPITER NEUROSCIENCES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.